CSPC Selected as One of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022”

Recently, renowned pharmaceutical media “Healthcare Executive” published its “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022” after four months of data analysis through a rigorous evaluation process[c1]  based on Derwent™ World Patents Index and Cortellis™ Competitive Intelligence and Clinical Trial Intelligence.  

CSPC is once again among the first tier of the list.

Healthcare Executive launched the list in 2019, which was generated through model building, data collection and collation based on three dimensions: innovation foundation, innovation process, and innovation results, together with four indicators: number of granted patents, the total number of patent citations, number of clinical trials, and number of approved and marketed innovative drugs. The list aims to reflect the innovation capability of Chinese pharmaceutical companies with valid and accurate data.

This is the fourth time that Healthcare Executive releases the list and also the fourth consecutive year of CSPC’s selection in the first tier of the list.

According to Healthcare Executive, the list intends to identify the companies leading China’s pharmaceutical innovation, which are the backbone of the transformation and upgrading of China’s pharmaceutical industry. Also, these enterprises can drive industrial competitiveness and provide valuable experience for latecomers as role models.

As an innovation-driven company, CSPC has been increasing its R&D investment since its inception. In the first half of 2022, CSPC Pharmaceutical Group Limited (1093.HK) invested a total of RMB 1.884 billion in R&D expenses (included in its income statement), an increase of 16.8% YoY, accounting for approximately 15.3% of its finished drug revenues. Currently, the group has about 300 projects under development, including more than 40 micromolecular drugs, over 40 macromolecular drugs and about 30 novel preparations. More than 50 of the projects are already under clinical research.

In 2022, Duoenda®(mitoxantrone hydrochloride liposome injection), an independently developed anti-tumor nano-drug by CSPC, and Kebituo (Duvelisib capsule), the first selective PI3K inhibitor approved in China, were launched in the Chinese market. The group’s desvenlafaxine succinate tablets for depression treatment and irinotecan liposome injection for the treatment of metastatic pancreatic cancer have been applied for marketing approval. Its Naleshu JMT103 (fully human monoclonal targeting RANKL) for treating unresectable or inoperable giant-cell tumor of bone (GCTB) was also submitted for marketing approval whilst included in the NMPA Priority Evaluation. The product is the first fully human IgG4 monoclonal targeting RANKL globally to apply for marketing.

CSPC also attaches great importance to the protection of its technical patent. In the first half of 2022, the group submitted 17 PCT filings and 112 patent filings (95 at home and 17 abroad), obtaining 24 patent grants (16 at home and 8 abroad).